DNTH logo

DIANTHUS THERAPEUTICS INC

DNTHNASDAQ
🏆 #1356 by market capEarnings Nov 3US Equity
$87.21▼ $0.56 (−0.64%)
After hours · at close
🔔
Track DNTH
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.6%
7d▼ 11.3%
14d▼ 16.7%
30d▼ 17.5%
ytd▲ 111.6%
1y▲ 120.4%
🏦Market Cap
$4.88B
Small Cap
📈Revenue Growth (YoY)
-67.3%
Declining
📊Gross Margin
96.0%
High
💵FCF Margin
-8178.0%
Thin
⚖️P/S Ratio
2505.9x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$85.98 – $88.91
52-Week Range
$32.22 – $117.88
Volume
$3.20B
Avg Volume
$3.93B
Shares Outstanding
55.9M
Next Earnings
Nov 16, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$761,000
P/E Ratio
-656.2
P/S Ratio
2505.9x
EPS (TTM)
$-0.53
Dividend Yield
0.00%
Dilution (1yr)
+7.9%

Why Investors Own DNTH

  • ✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 26% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DNTH logo

DIANTHUS THERAPEUTICS INC

DNTH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▼ −67.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$178M▲ +74.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$129M▲ +65.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37.8M▲ +7.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$50M▲ +$28M YoY
StockOtter · stockotter.space

About DIANTHUS THERAPEUTICS INC

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$93.73
▲ +7.5% Upside
High Target$102.88
Low Target$74.05
Based on 28 analysts

Latest News & Updates

🚀
Barron’s·2h ago

DIANTHUS THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift DNTH price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

DIANTHUS THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.